title: Juvenile Huntington's disease: a population-based study using the General Practice Research Database.
abstract: BACKGROUND
  The juvenile form of Huntington's disease (HD) is a rare disorder. There are no population-based estimates of either its incidence or prevalence in any population in the world. The present study was undertaken to estimate the frequency of juvenile HD in the UK and to examine the range of pharmacological treatments used in its management.
  
  
  METHODS
  The records of individuals under the age of 21 who had recorded diagnoses of HD were retrieved from the General Practice Research Database from 1990 through 2010. From these data estimates of incidence and prevalence were made as well as the specific treatments used in the treatment of its physical and psychological manifestations.
  
  
  RESULTS
  12 incident and 21 prevalent patients with juvenile HD were identified. The 21 prevalent cases included the 12 incident cases. The minimum population-based estimate of incidence is 0.70 (95% CI 0.36 to 1.22) per million patient-years. The minimum estimate of prevalence is 6.77/million (95% CI 5.60 to 8.12) per million patient-years. Patients were most frequently prescribed antidepressants, hypnotics, antipsychotics and treatments for motor abnormalities.
  
  
  CONCLUSIONS
  In the UK, juvenile HD is an extremely rare and complex disorder. The prescribing data demonstrate that the clinical management of juvenile HD is undertaken with no formal evidence base for the efficacy or safety of the treatments used. Research into the safety and efficacy of appropriate therapies is urgently required to offset the haphazard nature of prescribing. Multinational collaboration will be necessary to enrol sufficient numbers. Exploratory studies, though, should begin now.
authors.affiliation: Department of Epidemiology, London School of Hygiene and Tropical Medicine, University of London, London, UK.
authors.forename: Ian
authors.initials: I
authors.lastname: Douglas
authors.forename: Stephen
authors.initials: S
authors.lastname: Evans
authors.forename: Michael D
authors.initials: MD
authors.lastname: Rawlins
authors.forename: Liam
authors.initials: L
authors.lastname: Smeeth
authors.forename: Sarah J
authors.initials: SJ
authors.lastname: Tabrizi
authors.forename: Nancy S
authors.initials: NS
authors.lastname: Wexler
references.citation: Arch Neurol. 2007 Jun;64(6):813-9
references.pmid: 17562929
references.citation: PLoS Curr. 2012 Jul 20;4:e4f8606b742ef3
references.pmid: 22953238
references.citation: J Med Genet. 1995 Jul;32(7):524-30
references.pmid: 7562964
references.citation: Annu Rev Med. 2012;63:1-22
references.pmid: 22248319
references.citation: BMJ. 2010 Jun 30;340:c3109
references.pmid: 20591965
references.citation: PLoS Curr. 2012 Feb 15;4:RRN1304
references.pmid: 22474619
references.citation: Hum Genet. 1986 Jul;73(3):235-9
references.pmid: 2942452
references.citation: Br J Clin Pharmacol. 2010 Jan;69(1):4-14
references.pmid: 20078607